Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Acadia’s Nuplazid to treat Parkinson’s disease psychosis
The regulator has however asked Acadia to include a boxed warning on the drug’s label for an increased risk of death associated with its use in older people.
The regulator has however asked Acadia to include a boxed warning on the drug’s label for an increased risk of death associated with its use in older people.
The deal gives AbbVie rights to Stemcentrx’s experimental treatment for a form of lung cancer and other experimental drugs. Stemcentrx’s lead late-stage asset rovalpituzumab tesirine (Rova-T) is presently
Medivation develops and commercializes medically innovative therapies to treat severe diseases for which there are limited treatment options. The company has one marketed prostate cancer therapy, Xtandi, and
Lonsurf is indicated to treat adult patients with mCRC who have earlier been treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based
The open-label study will assess the safety and tolerability of the drug in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC)
The three conditions for which Ilaris is being reviewed include tumor necrosis factor-receptor associated periodic syndrome (TRAPS) and Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean
The orphan medicinal products designation is recommended for the two active ingredients of AB569, sodium nitrite and ethylenediaminetetraacetic acid (EDTA). The positive opinion will now be forwarded to
Xtampza ER is an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options
US-based Ironwood Pharmaceuticals will pay AstraZeneca up to $265m for US rights to the drug, even though the UK firm will continue to manufacture Zurampic and provide other
Descovy is indicated in the European Union (EU) to treat adults and adolescents aged 12 years and older with body weight at least 35 kg in combination with